Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupEndocrine and Neuroendocrine OncologyGastroenterologic OncologyThoracic TumorsDiseaseNeuroendocrine TumorsSubgroupICD10E34.0MeSHNeuroendocrine TumorsSequenceChemotherapyChemo-substanceEverolimusChemo-substanceEverolimusChemo-substanceEverolimusChemo-substanceEverolimusNo. Substances1 RadiotherapySupportive therapySupportive substanceSupportive substanceSupportive substanceSupportive substanceNo. SubstancesProtocol classificationTherapy classificationalternativeIntensityStandard doseTherapy indicationSecond lineTherapy phaseTherapy intentionpalliativeRisksAnemia Hb below 8g/dlAnemia Hb below 10g/dlDiarrheaEmetogenicity (ASCO)HyperglycemiaInfectionsNauseaOral MucositisRash only studiesPublicationAuthorYao JCDiseasefortgeschrittener, gut-diff., nicht funktionaler neuroendokriner Tumor der Lunge oder gastrointestinaler Herkunft, Grad 1 und 2, WHO Status 0-1OriginThe Fourth Trial (RADIANT-4) Study GroupProtocols in Revision 1 protocol foundProtocols under revision.Everolimus 10, Pulmonary and Gastroenteric Neuroendocrine Tumors (PID650 V1.2)
